Piper Sandler notes Tenaya Therapeutics (TNYA) reported positive initial MyPEAK-1 data. TN-201 showed encouraging 3 patient data that demonstrated effective cardiac transduction, with increased RNA expression, and a 53% increase in MyBP-C protein in Patient 1, the firm highlights. Additionally, TN-201 showed a clean safety profile, which opens the door for cohort 2 higher dosing given the recent DSMB clearance, says Piper. The firm continues to be bullish on Tenaya and views the initial positive MyPEAK-1 readout as a significant de-risking event for higher dosing and additional data expected in 2025. Piper has an Overweight rating on the shares with a price target of $40.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNYA:
- Tenaya Therapeutics Reports Promising TN-201 Trial Results
- Tenaya Therapeutics’ Senior VP Resigns for New Opportunity
- Tenaya reported early data from first cohort of patients in MyPEAK-1 trial
- Tenaya Therapeutics to announce initial data from Phase 1b/2 trial of TN-201
- Tenaya Therapeutics doses first patient with TN-401 gene therapy
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
